{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T23:04:41Z","timestamp":1648595081773},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s10557-019-06889-7","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T07:02:41Z","timestamp":1563778961000},"page":"425-433","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safe and Efficacious Use of 1-Month Triple Therapy in Patients with Atrial Fibrillation and High Bleeding Risk Undergoing PCI"],"prefix":"10.1007","volume":"33","author":[{"given":"Antonia","family":"Sambola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian V.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Limeres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno Garc\u00eda","family":"del Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Garc\u00eda-Dorado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,22]]},"reference":[{"key":"6889_CR1","doi-asserted-by":"publisher","first-page":"e24964","DOI":"10.1371\/journal.pone.0024964","volume":"6","author":"S Kralev","year":"2011","unstructured":"Kralev S, Schneider K, Lang S, Suselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One. 2011;6:e24964.","journal-title":"PLoS One"},{"key":"6889_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213\u201360.","journal-title":"Eur Heart J"},{"key":"6889_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","volume":"138","author":"DJ Angiolillo","year":"2018","unstructured":"Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective-2018 update. Circulation. 2018;138:527\u201336.","journal-title":"Circulation"},{"key":"6889_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1161\/CIRCINTERVENTIONS.112.968792","volume":"5","author":"JM Ruiz-Nodar","year":"2012","unstructured":"Ruiz-Nodar JM, Mar\u00edn F, Rold\u00e1n V, Valencia J, Manzano-Fern\u00e1ndez S, Caballero L, et al. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv. 2012;5:459\u201366.","journal-title":"Circ Cardiovasc Interv"},{"key":"6889_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.amjcard.2011.08.007","volume":"109","author":"R Romaguera","year":"2012","unstructured":"Romaguera R, Wakabayashi K, Laynez-Carnicero A, Sardi G, Maluenda G, Ben-Dor I, et al. Association between bleeding severity and long-term mortality in patients experiencing vascular complications after percutaneous coronary intervention. Am J Cardiol. 2012;109:75\u201381.","journal-title":"Am J Cardiol"},{"key":"6889_CR6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/hrt.2009.167064","volume":"18","author":"A Sambola","year":"2009","unstructured":"Sambola A, Ferreira-Gonz\u00e1lez I, Angel J, Alfonso F, Maristany J, Rodr\u00edguez O, et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart. 2009;18:1483\u20138.","journal-title":"Heart"},{"key":"6889_CR7","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","volume":"374","author":"R S\u00f8rensen","year":"2009","unstructured":"S\u00f8rensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, J\u00f8rgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967\u201374.","journal-title":"Lancet"},{"key":"6889_CR8","doi-asserted-by":"crossref","unstructured":"Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 126:1185\u201393.","DOI":"10.1161\/CIRCULATIONAHA.112.114967"},{"key":"6889_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1253\/circj.CJ-15-0923","volume":"80","author":"A Sambola","year":"2016","unstructured":"Sambola A, Mutuberr\u00eda M, Garc\u00eda Del Blanco B, Alonso A, Barrab\u00e9s JA, Alfonso F, et al. Effects of Triple therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention regarding thromboembolic risk stratification. Circ J. 2016;80:354\u201362.","journal-title":"Circ J"},{"key":"6889_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","volume":"170","author":"ML Hansen","year":"2010","unstructured":"Hansen ML, S\u00f8rensen R, Clausen MT, Fog-Petersen ML, Rauns\u00f8 J, Gadsb\u00f8ll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433\u201341.","journal-title":"Arch Intern Med"},{"key":"6889_CR11","doi-asserted-by":"publisher","first-page":"e0147245","DOI":"10.1371\/journal.pone.0147245","volume":"11","author":"A Sambola","year":"2016","unstructured":"Sambola A, Mutuberr\u00eda M, Garc\u00eda Del Blanco B, Alonso A, Barrab\u00e9s JA, Bueno H, et al. Impact of Triple therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention. PLoS One. 2016;11:e0147245.","journal-title":"PLoS One"},{"key":"6889_CR12","first-page":"2369","volume":"19","author":"AJ Camm","year":"2010","unstructured":"European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, et al. Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;19:2369\u2013429.","journal-title":"Eur Heart J"},{"key":"6889_CR13","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","volume":"65","author":"KA Fiedler","year":"2015","unstructured":"Fiedler KA, Maeng M, Mehilli J, Schulz-Sch\u00fcpke S, Byrne RA, Sibbing D, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65:1619\u201329.","journal-title":"J Am Coll Cardiol"},{"key":"6889_CR14","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jcin.2016.04.027","volume":"9","author":"KC Koskinas","year":"2016","unstructured":"Koskinas KC, Raber L, Zanchin T, Pilgrim T, Stortecky S, Hunziker L, et al. Duration of triple therapy antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention. JACC Cardiovascular Interv. 2016;9:1473\u201383.","journal-title":"JACC Cardiovascular Interv"},{"key":"6889_CR15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","volume":"126","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020\u201335.","journal-title":"Circulation"},{"key":"6889_CR16","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"6889_CR17","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"},{"key":"6889_CR18","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/eurheartj\/ehp045","volume":"30","author":"JM Ruiz-Nodar","year":"2009","unstructured":"Ruiz-Nodar JM, Mar\u00edn F, S\u00e1nchez-Pay\u00e1 J, Hurtado JA, Valencia-Mart\u00edn J, Manzano-Fern\u00e1ndez S, et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J. 2009;30:932\u20139.","journal-title":"Eur Heart J"},{"key":"6889_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87\u2013165.","journal-title":"Eur Heart J"},{"key":"6889_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107\u201315.","journal-title":"Lancet"},{"key":"6889_CR21","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423\u201334.","journal-title":"N Engl J Med"},{"key":"6889_CR22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. RE-DUAL PCI. Dual Antithrombotic Therapy With Dabigatran After Pci In Atrial Fibrillation. N Engl J Med. 2017;377:1513\u201324.","journal-title":"N Engl J Med"},{"key":"6889_CR23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509\u201324.","journal-title":"N Engl J Med"},{"key":"6889_CR24","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155\u201366.","journal-title":"N Engl J Med"},{"key":"6889_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","volume":"65","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, et al. ZEUS Investigators, Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805\u201315.","journal-title":"J Am Coll Cardiol"},{"key":"6889_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","volume":"391","author":"O Varenne","year":"2018","unstructured":"Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carri\u00e9 D, et al. SENIOR investigators, drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391:41\u201350.","journal-title":"Lancet"},{"key":"6889_CR27","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791\u2013800.","journal-title":"N Engl J Med"},{"key":"6889_CR28","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.chest.2015.12.029","volume":"149","author":"BH Raccah","year":"2016","unstructured":"Raccah BH, Perlman A, Danenberg HD, Pollak A, Muszkat M, Matok I. Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure: systematic review and metaanalysis of randomized trials. Chest. 2016;149:1516\u201324.","journal-title":"Chest"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-019-06889-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T23:32:28Z","timestamp":1595287948000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-019-06889-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,22]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["6889"],"URL":"https:\/\/doi.org\/10.1007\/s10557-019-06889-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,22]]},"assertion":[{"value":"22 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Sambola reports grant from Amgen to the institution, fees from lectures, Amgen, Boehringer-Ingelheim, Bristol-Myers, BMS-Pfizer, Astra-Zeneca, Novartis, Novo-nordisk outside the submitted work. Dr. Bueno reports grants from Instituto de Salud Carlos III; personal fees from Bayer; personal fees from Novartis; grants, personal fees, and non-financial support from AstraZeneca; grants and personal fees from BMS-Pfizer; personal fees from Ferrer; personal fees from MEDSCAPE-the Heart-org; and personal fees from Janssen, outside the submitted work. The remaining authors no have disclosures to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}